Uniwersyteckie Centrum Kliniczne, Klinika Pediatrii, Diabetologii i Endokrynologii
Welcome,         Profile    Billing    Logout  
 3 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Linn, Thomas
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
NCT03977064: Fertility and Cardiovascular Risk in Men With Metabolic Syndrome

Recruiting
N/A
70
Europe
Life style change and weight reduction
University of Giessen
Metabolic Syndrome
12/23
12/24
Adana, Maria Soledad Ruiz de
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
Vass, Viktor
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
Braun, Hermann
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
Lubi, Maire
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
Peet, Aleksandr
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
NCT06372392: Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps

Recruiting
N/A
20
Europe
Universal meal coefficient utilization
Tartu University Hospital, Estonia Research Council
Type1diabetes
06/24
12/24

Download Options